Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 120101 | ISIN: CA09852M1014 | Ticker-Symbol: N/A
1-Jahres-Chart
PORTAGE BIOTECH INC Chart 1 Jahr
5-Tage-Chart
PORTAGE BIOTECH INC 5-Tage-Chart

Aktuelle News zur PORTAGE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoImmuno-oncology company Portage Biotech to evaluate strategic alternatives2
12.04.PORTAGE BIOTECH INC. - 6-K, Report of foreign issuer1
12.04.Portage Biotech hints at potential closure as it halts programs, hunts for strategic options1
12.04.Portage Biotech Halts ADPORT-601 Trial Enrollment, To Explore Strategic Alternatives1
12.04.Portage Biotech Inc.: Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives400WESTPORT, Conn., April 12, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and...
► Artikel lesen
26.03.Portage Biotech Inc.: Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares1
07.03.PORTAGE BIOTECH INC. - 6-K, Report of foreign issuer1
29.02.Portage Biotech Inc reports results for the quarter ended in December - Earnings Summary1
29.02.PORTAGE BIOTECH INC. - 6-K, Report of foreign issuer-
28.02.Portage Biotech Inc.: Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update99WESTPORT, Conn., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies...
► Artikel lesen
26.02.Portage Biotech Inc expected to post a loss of 27 cents a share - Earnings Preview1
18.01.PORTAGE BIOTECH INC. - 6-K, Report of foreign issuer7
04.01.Portage Biotech to halt iNKT drug program, cut workforce1
04.01.Portage Biotech To Pause INKT Clinical Development; To Evaluate Potential Strategic Options-
04.01.PORTAGE BIOTECH INC. - 6-K, Report of foreign issuer1
04.01.Portage Biotech Inc.: Portage Biotech Reports Business and Strategic Update191Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resourcesCompany will evaluate range of strategic options WESTPORT, Conn., Jan. 04, 2024 (GLOBE NEWSWIRE) --...
► Artikel lesen
01.12.23PORTAGE BIOTECH INC. - S-8, Securities to be offered to employees in employee benefit plans1
28.11.23Portage Biotech GAAP EPS of -$0.291
28.11.23PORTAGE BIOTECH INC. - 6-K, Report of foreign issuer1
28.11.23Portage Biotech Inc.: Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023, and Business Update132WESTPORT, Conn., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and...
► Artikel lesen
Seite:  Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1